News and Events
June 27, 2021 News
Indivumed Expands Cancer Drug Discovery Efforts
We are happy to share our recent GenomeWeb feature story and interview with CEO Prof. Dr. Hartmut Juhl and CBO Roald Forsberg, PhD as well as one of our partners Dr. David Kerr from University of Oxford talking about the launch of nRavel, Drug Discovery Efforts, Achievements and Goals. Thanks to GenomeWeb and Neil Versel for writing this piece.
Read moreJune 09, 2021 News
Indivumed becomes Certified Service Provider of the Spatial Transcriptomics technology by 10x Genomics
Indivumed became a “Certified Service Provider” of the Spatial Transcriptomics technology (Visium Spatial Gene Expression) by 10x Genomics. In combination with the high quality multi-omics tissue Indivumed offers the whole workflow for customer research projects.
Read moreJune 02, 2021 Press
Indivumed Launches nRavel™ AI Platform
Indivumed GmbH today announced the launch of nRavel™, a unique AI discovery platform for oncology and precision medicine. The platform combines IndivuType’s deep multi-omics data with elaborate disease models, high-powered automated Machine Learning tools, and a comprehensive suite of advanced analytics tools. Together this creates an unparalleled engine for generating new discoveries and insights into cancer biology.
Read moreMay 17, 2021 Press
Indivumed Joins KHR Biotec
Indivumed GmbH CEO Dr. Hartmut Juhl and University Medical Center Mainz Professor Krishnaraj Rajalingam today announced Indivumed will be joining the newly formed KHR Biotech GmbH – a spin-off biopharma company from University Mainz. The new company will combine Prof. Rajalingam’s research and scientific approach with Indivumed’s database and AI capabilities in order to bring new compounds targeting pertinent oncogenic signaling pathways into the clinical phase.
Read moreResearch Publications
Product Information
Biospecimen Products
To meet all your needs in cancer research and drug development we offer you a broad spectrum of high-quality biospecimen samples including clinical data.
Applications and CRO Services
To further support your efforts in personalized oncology we offer you an holistic range of clinical, laboratory, and research services.
ISO-Certified Expertise
Indivumed GmbH’s long-standing expertise is ISO 9001:2015-certified and includes the collection of biological samples and clinical data (Biobank), research service in the form of immunohistochemistry, analysis of signaling proteins, drug testing, establishment of primary cell cultures and molecular biology, bioinformatic and biomedical data analysis.
Download the ISO-Certificate
Media
Discover more about Indivumed’s work and the future of personalized cancer medicine in the following lectures and videos.
IndivuType
The global multi-omics cancer solution
In Focus:
Precision Oncology – Interview with Prof. Dr. Hartmut Juhl, Indivumed Group
In Focus:
Partnerships – Interview with Prof. Dr. Hartmut Juhl, Indivumed Group
In Focus:
nRavel – Interview with Dr. Jonathan Woodsmith, Indivumed Group
In Focus:
Data Depth – Interview with Dr. Jonathan Woodsmith, Indivumed Group
In Focus:
Data Quality – Interview with Dr. Jonathan Woodsmith, Indivumed Group
In Focus:
Our Vision – Interview with Dr. Jonathan Woodsmith, Indivumed Group
In Focus:
ASCO 2021 – Interview with Roald Forsberg, PhD, Indivumed Group
In Focus:
Our Mission – Interview with Roald Forsberg, PhD, Indivumed Group
In Focus:
IndivuType – Interview with Roald Forsberg, PhD, Indivumed Group
In Focus:
AI – Interview with John L. Marshall, MD, Georgetown University Hospital
In Focus:
ASCO 2021 – Interview with John L. Marshall, MD, Georgetown University Hospital
In Focus:
Precision Oncology – Interview with John L. Marshall, MD, Georgetown University Hospital
Partners
Global Clinical Network
Global Clinical Network
Interview Prof. Jesus Garcia Foncillas – Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain
Global Clinical Network
Interview Dr. Rafael López López – Hospital Clínico Universitario de Santiago, Barcelona, Spain
Global Clinical Network
Interview Dr. Xavier Matias-Guiu – Hospital Universitario Arnau de Vilanova Lleida, Lleida, Spain
Global Clinical Network
Interview Prof. Gerry Melino – Hospital Tor Vergata Italy, Rome, Italy
Global Clinical Network
Interview Prof. Sun Young Rha – Severance Hospital Yonsei University Health System, Seoul, South Korea
Global Clinical Network
Interview Dr. Carlos Sampaio – Clinica AMO Brazil, Salvador, Brazil
Global Clinical Network
Interview Prof. Takayuki Yoshino – National Cancer Center Hospital East Japan, Chiba, Japan
Cooperational Partnerships
Cooperational Partnership
Interview with Roald Forsberg, PhD about Gnosis Partnership – Gnosis Data Analysis
Cooperational Partnership
Interview with Oliver Rinner, PhD about Biognosys Partnership – Biognosys AG
Scientific Lectures
Scientific Lectures
22CEMIT Symposium: Overview and Perspectives for Translating Multi-omics into Clinical Utility in Solid Tumors
Speaker: Prof. Dr. Hartmut Juhl
Scientific Lectures
Next In Personalized Medicine - Cancer-Phenotyping
Speaker: Hartmut K. Land, Ph.D., Prof. Dr. Hartmut Juhl
Scientific Lectures
Personalized Oncology – Why Tissue Is the Issue When Characterizing Tumor Expression
Speaker: Dr. Bernd Gromoll, Prof. Dr. Hartmut Juhl
Scientific Lectures
Opening Remarks and The Importance of Biobanking on Personalized Medicine
Speaker: Carolyn Compton, M.D., PhD
Scientific Lectures
The Challlenge and Importance of Standardizing Pre-Analytical Variables in Surgical Pathology Specimens for Clinical Care and Translational Research
Speaker: David Hicks, M.D.
Scientific Lectures
How to Assess Tissue Quality to Improve Tissue Diagnostics
Speaker: Jim Crawford, M.D., PhD
Scientific Lectures
The Future of Personalized Medicine in Oncology Has Begun
Speaker: John Marshall, M.D., PhD
Scientific Lectures
IndivuType: Indivumed's Global Cancer Database Solution for Drug Development and Patient Care
Speaker: Prof. Dr. Hartmut Juhl